针对65岁及以上成年人的初级保健物理运动处方计划的有效性:PREFIS-AP
基层医疗中体力运动处方项目对改善农村卫生区65岁及以上成年人身体素质和生命质量的有效性:PREFIS-AP随机对照试验
This randomized controlled trial aims to evaluate the effectiveness of an individualized Physical Exercise Prescription Program delivered in Primary Care for adults aged 65 years and older. The intervention includes a structured assessment of physical fitness, muscle function and mass, physical activity level, and quality of life, followed by a tailored exercise plan encompassing aerobic, strength, respiratory, flexibility, and balance training. Outcomes will be compared with a control group receiving standard health advice to walk briskly for at least 30 minutes daily. The study also explores associations between polypharmacy, muscle function, physical performance, and quality of life.
研究概览
详细说明
Sedentary behavior is strongly associated with multiple adverse health outcomes, particularly in older adults. Conventional lifestyle advice alone has shown limited effectiveness in increasing physical activity levels. Exercise prescription delivered through structured evaluation, individualized planning, and scheduled follow-up may lead to clinically significant improvements in physical function and quality of life.
This study will recruit 210 adults aged ≥65 years from a rural Primary Care center. Participants will undergo baseline assessments including sociodemographic variables, anthropometric measures, muscle strength (handgrip dynamometry and chair stand test), aerobic capacity (6-minute walk test), muscle mass (calf circumference and ultrasound of rectus femoris), physical activity level (GPAQ), and quality of life (SF-36). After randomization (1:1), the intervention group will receive a personalized exercise prescription generated through the MEDORA Primary Care electronic system and supervised by a qualified Exercise Technician. The control group will receive routine health advice.
After three months, all participants will be reassessed using the same measures. The study will analyze the effect of the intervention on physical fitness, physical activity, muscle mass and function, and quality of life, including sex-specific differences and the role of polypharmacy. The project incorporates a partial masking strategy and uses REDCap for data management and anonymization.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Víctor Manuel González Rodríguez, MD
- 电话号码:54196 +34923 356 677
- 邮箱:vmgonzalez@saludcastillayleon.es
学习地点
-
-
Salamanca
-
Villoría、Salamanca、西班牙、37339
- 招聘中
- Centro de Salud de Villoria
-
接触:
- Víctor Manuel González Rodríguez, MD
- 电话号码:54196 34 923 356 677
- 邮箱:vmgonzalez@saludcastillayleon.es
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥ 65 years
- Motivated to participate and able to provide informed consent
- Able to attend baseline assessment and follow-up
- Clinical stability allowing participation in exercise evaluation
Exclusion Criteria:
- Recent myocardial infarction
- Unstable angina
- Uncontrolled arrhythmias (symptomatic or hemodynamically compromising)
- Syncope
- Acute endocarditis, myocarditis, or pericarditis
- Severe or symptomatic aortic stenosis
- Uncontrolled heart failure
- Recent pulmonary thromboembolism or pulmonary infarction
- Lower-limb thrombosis
- Severe aortic stenosis or suspected dissecting aortic aneurysm
- Uncontrolled asthma
- Pulmonary edema
- Acute respiratory failure
- Acute non-cardiopulmonary illness that impairs exercise capacity (e.g., infection, thyrotoxicosis, acute renal failure)
- Mental disorder that prevents adequate cooperation.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Physical Exercise Prescription Program
Participants receive a 12-week individualized multicomponent Exercise Prescription Programme integrated into routine Primary Care and supported by the MEDORA® electronic health record. Exercise prescription is based on baseline clinical and functional assessment and includes aerobic, resistance, balance and flexibility exercise, with respiratory muscle training when considered clinically indicated. Exercise is performed both independently at home and during supervised group reinforcement sessions available three days per week in municipal sports facilities. During supervised sessions, each participant follows his or her individualized exercise prescription rather than a uniform group exercise programme. Exercise type, intensity, duration, frequency and progression are individualized according to baseline clinical and functional status, tolerance and progression. |
Participants receive a structured and individualized 12-week program including: Aerobic exercise (continuous and interval training, intensity guided by Borg scale) Strength training using elastic bands (progressively increasing repetitions, series, and load) Respiratory exercises with pressure-based devices Flexibility exercises (static stretching routines) Balance training (single-leg stance, heel-toe walking, eyes-closed tasks) The program is generated through the MEDORA electronic system after baseline evaluation. A certified Exercise Technician provides instruction, supervision, and progression adjustments. Exercise type, intensity, duration, frequency and progression are individualized within the exercise-prescription framework according to baseline clinical and functional assessment |
|
无干预:Standard Health Advice
Participants allocated to the control group receive usual Primary Care and general physical-activity advice consistent with World Health Organization recommendations. They do not receive an individualized structured exercise prescription, supervised reinforcement sessions, or intervention-specific follow-up. The study did not systematically prescribe control participants to walk briskly for at least 30 minutes per day. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Quality of Life
大体时间:Baseline to 3 months.
|
Quality of Life will be measured by the SF-36 questionnaire. The SF-36 questionnaire is a widely used, patient-reported questionnaire measuring health-related quality of life. It uses points to assess health, with responses on Likert scales (e.g., 0 to 100) transformed into scores for 8 health domains: physical functioning, role limitations (physical/emotional), bodily pain, general health, vitality, social functioning, and mental health, where higher scores mean better health, ranging from 0 (maximum disability) to 100 (no disability). |
Baseline to 3 months.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Physical Activity Level (GPAQ)
大体时间:Baseline to 3 months.
|
Change in physical activity level as measured by the Global Physical Activity Questionnaire (GPAQ), including time spent in work-related activity, transport-related activity, leisure-time activity, and sedentary behavior. Participants will be classified into WHO categories (high, moderate, or low/inactive) based on standardized scoring procedures. |
Baseline to 3 months.
|
|
Aerobic Capacity (6-Minute Walk Test)
大体时间:Baseline to 3 months.
|
Change in functional aerobic capacity assessed by the 6-minute walk test (6MWT). The primary variable will be the total distance walked in meters during 6 minutes. Physiological responses (heart rate, oxygen saturation, perceived exertion using Borg scale) will also be recorded. |
Baseline to 3 months.
|
|
Muscle Strength - Handgrip Dynamometry
大体时间:Baseline to 3 months.
|
Change in maximal isometric handgrip strength measured with a JAMAR dynamometer (kg), using the highest value from standardized bilateral measurements. Cut-off values will follow European sarcopenia consensus criteria (<27 kg for men; <16 kg for women). |
Baseline to 3 months.
|
|
Muscle Strength - Chair Stand Test
大体时间:Baseline to 3 months.
|
Change in lower-limb functional strength measured by the 30-second chair stand test. The outcome is the total number of complete sit-to-stand repetitions performed within 30 seconds following standardized protocol. |
Baseline to 3 months.
|
|
Muscle Mass - Calf Circumference
大体时间:Baseline to 3 months.
|
Change in muscle mass estimated by calf circumference (cm), measured at the widest point of the calf using a flexible tape. A value <31 cm will be considered indicative of potential muscle mass deficit. |
Baseline to 3 months.
|
|
Muscle Mass - Ultrasound of Rectus Femoris
大体时间:Baseline to 3 months.
|
Change in quantitative and qualitative muscle parameters assessed by ultrasound of the rectus femoris (muscle thickness, cross-sectional area, and echogenicity), following validated measurement criteria for sarcopenia assessment. |
Baseline to 3 months.
|
|
Sex Differences in Response to the Exercise Prescription Program (Standardized Change Score)
大体时间:Baseline to 3 months.
|
This outcome will assess whether biological sex modifies the effect of the intervention on functional and health-related outcomes. Sex-specific differences will be evaluated using standardized change scores (z-scores). The standardized composite score will be derived from the following previously defined outcome measures: Muscle strength (handgrip dynamometry (kg) and the 30-second chair stand test) Aerobic capacity (6-minute walk test) Muscle mass, assessed by calf circumference (cm) and ultrasound measurements of rectus femoris muscle thickness Physical activity level, (Global Physical Activity Questionnaire (GPAQ) Health-related quality of life (SF-36 questionnaire) Each variable will be standardized before aggregation to ensure comparability across different units of measurement. The resulting composite score will be compared between men and women to determine if sex influences the magnitude of response to the exercise prescription program. |
Baseline to 3 months.
|
|
Correlation Between Polypharmacy and Change in Handgrip Strength
大体时间:Baseline to 3 months
|
This outcome will assess the correlation between baseline medication burden and change in muscle strength in older adults from baseline to 3 months. Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications). Muscle strength will be assessed by handgrip strength, measured in kilograms (kg) using a calibrated hand dynamometer. Change in handgrip strength will be calculated as the difference between baseline and 3-month values. |
Baseline to 3 months
|
|
Correlation Between Polypharmacy and Change in Appendicular Skeletal Muscle Mass
大体时间:Baseline to 3 months
|
This outcome will assess the correlation between baseline medication burden and change in muscle mass in older adults from baseline to 3 months. Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications). Muscle mass will be assessed as appendicular skeletal muscle mass, measured in kilograms (kg) using dual-energy X-ray absorptiometry (DXA). Change in muscle mass will be calculated as the difference between baseline and 3-month values. |
Baseline to 3 months
|
|
Correlation Between Polypharmacy and Change in Physical Performance
大体时间:Baseline to 3 months
|
This outcome will assess the correlation between baseline medication burden and change in physical performance in older adults from baseline to 3 months. Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications). Physical performance will be assessed using the Short Physical Performance Battery (SPPB), reported as a total score (points on a standardized scale). Change in SPPB score will be calculated as the difference between baseline and 3-month values. |
Baseline to 3 months
|
|
Correlation Between Polypharmacy and Change in Quality of Life
大体时间:Baseline to 3 months
|
This outcome will assess the correlation between baseline medication burden and change in quality of life in older adults from baseline to 3 months. Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications). Quality of life will be assessed using the EuroQol-5 Dimension (EQ-5D) questionnaire, reported as a standardized index score. Change in EQ-5D score will be calculated as the difference between baseline and 3-month values. |
Baseline to 3 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- PREFIS-AP
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.
IPD 共享时间框架
Data will be available starting 12 months after publication of primary results and for a minimum of 5 years thereafter.
IPD 共享访问标准
Qualified researchers with a methodologically sound proposal, as determined by the study steering committee, will be able to access the data. Requests should be directed to the study PI. A data access agreement will be required.
IPD 共享支持信息类型
- 研究方案
- 树液
- 分析代码
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.